Abstract YO38
Case summary
Thymomas constitute 10% of mediastinal tumours and are often benign epithelial neoplasms of the thymus gland. Up to a third of cases of thymomas are malignant and causes local infiltration to surrounding structures. Rarely, they metastasize to distant organs. We report a case of slow growing thymoma which progressed into cerebral metastases. A 53 year old lady presented with 5 years history of a mediastinal tumour. She initially refused any therapy at the first presentation. She returned with an enlarging anterior mediastinal mass causing chest pain and cough. Thoracic CT revealed a 10 cm right anterior mediastinal mass abutting the pericardium. Histopathological examination of the mediastinal mass biopsy indicated thymoma. She was planned for surgical resection however developed acute neurological symptoms of headache, confusion and memory loss. Cranial MRI showed multiple lesions in the temporoparietal lobe, left frontal lobe, internal capsule and basal ganglia. Stereotactic biopsy confirmed metastases from a B1 type thymoma. She deteriorated rapidly and died without any possible intervention. Intracranial metastases from thymic tumours are rare. To date, there are 45 cases reported within the literature of cerebral metastases from thymic epithelial tumours. The median survival with multiple cerebral metastases is merely 64 days, hence high suspicion of distant spread in thymic epithelial tumours and prompt surgery may potential improve the outcome in this group of patients.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract